Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: Modification of the a segment

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 21, 2004, Pages 5317-5322

  Yamashita, Ayako ^a,b   Norton, Emily B ^a   Kaplan, Joshua A ^a   Niu, Chuan ^a   Loganzo, Frank ^a   Hernandez, Richard ^a   Beyer, Carl F ^a   Annable, Tami ^a   Musto, Sylvia ^a   Discafani, Carolyn ^a   Zask, Arie ^a   Ayral Kaloustian, Semiramis ^a  

^a WYETH RESEARCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; HEMIASTERLIN DERIVATIVE; TALTOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN KB; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CELL PROLIFERATION; HUMANS; KB CELLS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; OLIGOPEPTIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 5344252376     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.08.024     Document Type: Article

References (25)

1. R. Talpir, Y. Benayahu, Y. Kashman, L. Pannell, and M. Schleyer Tetrahedron Lett. 35 1994 4453
2. J.E. Colemann, B.O. Patrick, R.J. Andersen, and S.J. Rettig Acta Cryst. C52 1996 1525
3. J.E. Coleman, E.D. de Silva, F. Kong, R.J. Andersen, and T.M. Allen Tetrahedron 51 1995 10653
4. P. Crews, J.J. Faris, R. Emrich, and P.A. Keifer J. Org. Chem. 59 1994 2932
5. H.J. Anderson, J.E. Coleman, R.J. Andersen, and M. Roberge Cancer Chemother. Pharmacol. 39 1997 223
6. R.J. Andersen, and J.E. Coleman Tetrahedron Lett. 38 1997 317
7. Andersen, R. J. WO 99/32509
8. J.A. Nieman, J.E. Coleman, D. Wallace, E. Piers, L.Y. Lim, M. Roberge, and R.J. Andersen J. Nat. Prod. 66 2 2003 183
9. F. Loganzo, C.M. Discafani, T. Annable, C. Beyer, S. Musto, M. Hari, X. Tan, C. Hardy, R. Hernandez, M. Baxter, T. Singanallore, G. Khafizova, M.S. Poruchysky, T. Fojo, J.A. Nieman, S. Ayral-Kaloustian, A. Zask, R.J. Andersen, and L.M. Greenberger Cancer Res. 63 2003 1838
10. Zask, A.; Birnberg, G.; Cheung, K.; Kaplan, J.; Niu, C.; Norton, B.; Suayan, R.; Yamashita, A.; Cole, D.; Tang, Z.; Krishnamurthy, G.; Williamson, R.; Khafizova, G.; Musto, S.; Hernandez, R.; Annable, T.; Yang, X.; Discafani, C.; Beyer, C.; Greenberger, L. M.; Loganzo, F.; Ayral-Kaloustian, S. J. Med. Chem., in press. Other references cited therein. Also see Ref. 5
11. J. Plochl Ber. 16 1883 2815
12. E. Erlenmeyer Justus Liebigs Ann. Chem. 275 1893 1
13. J. Meiwes, M. Schudok, and G. Kretzschmar Tetrahedron: Asymmetry 8 1997 527
14. J.E. Audia, D.A. Evrard, G.R. Murdoc, J.J. Droste, J.S. Nissen, K.W. Schenck, R. Fluzinski, V.L. Lucaites, D.L. Nelson, and M.L. Cohen J. Med. Chem. 39 1996 2773 and other references cited therein
15. Optically pure l- and d-amino acids were obtained by kinetic resolution. Wu, Y.; Megati, S.; Panolil, R.; Padmanathan, T.; Kendall, J.; Glestos, C.; Wilk, B., unpublished results
16. Compound 8 was prepared as described: E.J. Corey, M. Jautelat, and W. Oppolzer Tetrahedron Lett. 1967 2325
17. H. Matsuyama, T. Nakamura, and M. Iyoda J. Org. Chem. 65 2000 4796
18. K. Ishihara, N. Hanaki, and H. Yamamoto Synlett 1995 721
19. Compound 15 (hydrochloride salt) was prepared in five steps from commercially available N-tert-butoxycarbonyl-l-valine-N′,O- dimethylhydroxamide according to the literature procedures. See Ref. 7
20. The absolute stereochemistry of the two diastereomeric isomers was determined by NMR studies and physical properties of the product as described in the literature: see Ref. 7
21. 1H NMR, LC-MS, HPLC analysis)
22. 50 nM: KB-3-1 263-3000
23. The abbreviations used are: MAP, microtubule-assisted protein; SRB, sulforhodamine B; MDR 1, multidrug resistance protein-1
24. Multiple drug-resistant human KB-3-1 cells were provided by Dr. M. Gottesman, National Cancer Institute. See Ref. D.W. Shen, C. Cardarelli, J. Hwang, M. Cornwell, N. Richert, S. Ishii, I. Pastan, and M.M. Gottesman J. Biol. Chem. 261 1986 7762
25. S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collins, T. Annable, and L.M. Greenberger Cancer Res. 58 1998 5850 See also Ref. 7, and other references cited therein